Clinical Trials · NCT06820476

A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants After 10 Days of Oral Dosing

CompletedPhase 1Amycretin (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
Novo Nordisk A/S
Enrollment
29
Start date
Feb 2025
Locations
2 sites, China
Primary endpoint
Number of treatment emergent adverse events (TEAEs)
View Amycretin compound reference